{
    "organizations": [],
    "uuid": "eb86cc369c681607cbe4b70dcd38a10e5bf34fef",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/22/pr-newswire-nevro-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-2018-outlook.html",
    "ord_in_thread": 0,
    "title": "Nevro Reports Fourth Quarter and Full Year 2017 Financial Results and Provides 2018 Outlook",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "REDWOOD CITY, Calif., Feb. 22, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months and full year ended December 31, 2017.\n2017 Accomplishment & Highlights:\nAchieved revenue of $326.7 million for the full year 2017, an increase of 43%, as reported, over the prior year U.S. revenue of $263.5 million for 2017, an increase of 52% over the prior year International revenue of $63.2 million for 2017, an increase of 13% in constant currency and 15% on an as-reported basis, both over the prior year Achieved positive EBITDA and operating cash flow for each of the third and fourth quarters of 2017, excluding litigation expense Received CE Mark for next generation Senza II Received CE Mark for Senza I Conditional Full Body MRI Initiated Randomized Controlled Trials (RCT) in two new indications Presented positive clinical trial results during the 16 th Annual Pain Medicine Meeting, 2017: Demonstrated an approximate 78% reduction in VAS pain score in neck and an approximate 86% reduction in VAS pain score in upper limb at twelve-months for interim data from SENZA-ULN, a prospective, multicenter clinical trial evaluating HF10 therapy for the treatment of chronic intractable neck and/or upper limb pain Demonstrated an approximate 75% reduction in VAS pain score at three-months for interim data from SENZA-PPN, a prospective, multicenter clinical trial evaluating HF10 therapy for the treatment of peripheral polyneuropathy, which led to the initiation of a large-scale randomized trial for painful diabetic neuropathy (SENZA-PDN) Demonstrated an approximate 70% reduction in VAS pain score at three-months for interim data from a multicenter feasibility study evaluating HF10 therapy for the treatment of chronic abdominal pain Selected by Neurosurgery, the official journal of the Congress of Neurological Surgeons (CNS), as Top Pain Paper of the Year for the SENZA-RCT 24-month outcomes publication\nFourth Quarter Financial Results\nRevenue for the quarter ended December 31, 2017 was $98.0 million versus $70.5 million during the same period of the prior year, representing 39% growth as reported. U.S. revenue for the three months ended December 31, 2017 was $81.1 million, representing 45% growth as reported. International revenue was $16.9 million, representing growth of 10% in constant currency and 17% on an as-reported basis. The increase in revenue was primarily attributable to the continued adoption of the Senza system.\nGross profit for the fourth quarter of 2017 was $69.5 million, representing a 71% gross margin, up from $48.8 million, representing a 69% gross margin, in the same period of the prior year.\nOperating expenses for the fourth quarter of 2017 were $71.7 million compared to $55.1 million in the same period of the prior year, representing an increase of 30%. The increase in operating expenses was driven primarily by increased headcount and related personnel costs, as well as legal expenses associated with intellectual property litigations.\nLoss from operations for the fourth quarter of 2017 was $2.2 million compared to $6.3 million for the same period of the prior year.\nRevenue Guidance for Full Year 2018\nNevro reiterates worldwide revenue for 2018 to be in the range of $400.0 to $410.0 million, which was first announced in January 2018.\nWebcast and Conference Call Information\nManagement will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may dial (866) 393-4306 for domestic callers, or (734) 385-2616 for international callers (Conference ID: 2584428), or access the webcast on the \"Investors\" section of the company's web site at: www.nevro.com/investors .\nAbout Nevro\nHeadquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.\nForward-Looking Statements\nIn addition to historical information, this press release contains with respect to our business, capital resources, revenue projections, strategic initiatives and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including continuing adoption of, and interest in, Senza in the U.S. and international markets; and our expectations for worldwide revenue for the full year 2018. These are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K that we expect to file on February 22, 2018, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such Our results for the full year and quarter ended December 31, 2017 are not necessarily indicative of our operating results for any future periods.\nInvestor Relations Contact:\nNevro Investor Relations\nKatherine Bock\n(650) 433-3247\nir@nevro.com\nNevro Corp.\nConsolidated Statements of Operations and Comprehensive Loss\n(in thousands, except share and per share data)\nThree Months Ended\nYear Ended\nDecember 31,\nDecember 31,\n2017\n2016\n2017\n2016\n(unaudited)\nRevenue\n$\n97,963\n$\n70,531\n$\n326,674\n$\n228,504\nCost of revenue\n28,451\n21,692\n98,981\n75,433\nGross profit\n69,512\n48,839\n227,693\n153,071\nOperating expenses:\nResearch and development\n9,943\n11,276\n37,560\n33,729\nSales, general and administrative\n61,741\n43,832\n219,712\n142,423\nTotal operating expenses\n71,684\n55,108\n257,272\n176,152\nLoss from operations\n(2,172)\n(6,269)\n(29,579)\n(23,081)\nOther income (expense):\nInterest income (expense), net\n(1,616)\n(1,780)\n(6,738)\n(4,709)\nOther income (expense), net\n(131)\n(1,193)\n1,067\n(1,097)\nLoss on extinguishment of debt\n—\n—\n—\n(1,268)\nLoss before income taxes\n(3,919)\n(9,242)\n(35,250)\n(30,155)\nProvision for income taxes\n392\n583\n1,408\n1,623\nNet loss\n(4,311)\n(9,825)\n(36,658)\n(31,778)\nChanges in foreign currency translation\nadjustment\n(319)\n283\n(360)\n(163)\nChanges in gains (losses) on short-term\ninvestments\n(311)\n(44)\n(204)\n(340)\nNet change in other comprehensive loss\n(630)\n239\n(564)\n(503)\nComprehensive Loss\n$\n(4,941)\n$\n(9,586)\n$\n(37,222)\n$\n(32,281)\nNet loss per share, basic and diluted\n$\n(0.15)\n$\n(0.34)\n$\n(1.25)\n$\n(1.12)\nWeighted average shares used to compute\nnet loss per share, basic and diluted\n29,664,926\n28,817,333\n29,424,054\n28,485,003\nNevro Corp.\nConsolidated Balance Sheets\n(in thousands, except share and per share data)\nDecember 31,\nDecember 31,\n2017\n2016\nAssets\nCurrent assets\n$\n42,845\n$\n41,406\nShort-term investments\n226,467\n234,951\nAccounts receivable, net\n67,287\n52,818\nInventories, net\n98,119\n85,221\n6,463\n5,895\nTotal current assets\n441,181\n420,291\nProperty and equipment, net\n8,819\n7,132\nOther assets\n3,250\n2,354\nRestricted cash\n806\n806\nTotal assets\n$\n454,056\n$\n430,583\nLiabilities and stockholders' equity\nCurrent liabilities\nAccounts payable\n$\n18,492\n$\n16,162\nAccrued liabilities and other\n39,512\n26,036\nTotal current liabilities\n58,004\n42,198\nLong-term debt\n145,019\n138,140\n1,861\n1,211\nTotal liabilities\n204,884\n181,549\nStockholders' equity\nCommon stock, $0.001 par value, 290,000,000 shares authorized,\n29,737,561 and 28,886,862 shares issued and outstanding at\nDecember 31, 2017 and 2016, respectively\n30\n29\nAdditional paid-in capital\n508,228\n470,869\nAccumulated other comprehensive loss\n(1,242)\n(678)\nAccumulated deficit\n(257,844)\n(221,186)\nTotal stockholders' equity\n249,172\n249,034\nTotal liabilities and stockholders' equity\n$\n454,056\n$\n430,583\nView original content with multimedia: http://www.prnewswire.com/news-releases/nevro-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-2018-outlook-300603005.html\nSOURCE Nevro Corp.",
    "published": "2018-02-23T00:10:00.000+02:00",
    "crawled": "2018-02-23T00:56:03.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "redwood",
        "city",
        "nevro",
        "nyse",
        "nvro",
        "global",
        "medical",
        "device",
        "company",
        "providing",
        "innovative",
        "solution",
        "treatment",
        "chronic",
        "pain",
        "today",
        "reported",
        "financial",
        "result",
        "three",
        "month",
        "full",
        "year",
        "ended",
        "december",
        "accomplishment",
        "highlight",
        "achieved",
        "revenue",
        "million",
        "full",
        "year",
        "increase",
        "reported",
        "prior",
        "year",
        "revenue",
        "million",
        "increase",
        "prior",
        "year",
        "international",
        "revenue",
        "million",
        "increase",
        "constant",
        "currency",
        "basis",
        "prior",
        "year",
        "achieved",
        "positive",
        "ebitda",
        "operating",
        "cash",
        "flow",
        "third",
        "fourth",
        "quarter",
        "excluding",
        "litigation",
        "expense",
        "received",
        "ce",
        "mark",
        "next",
        "generation",
        "senza",
        "ii",
        "received",
        "ce",
        "mark",
        "senza",
        "conditional",
        "full",
        "body",
        "mri",
        "initiated",
        "randomized",
        "controlled",
        "trial",
        "rct",
        "two",
        "new",
        "indication",
        "presented",
        "positive",
        "clinical",
        "trial",
        "result",
        "th",
        "annual",
        "pain",
        "medicine",
        "meeting",
        "demonstrated",
        "approximate",
        "reduction",
        "va",
        "pain",
        "score",
        "neck",
        "approximate",
        "reduction",
        "va",
        "pain",
        "score",
        "upper",
        "limb",
        "interim",
        "data",
        "prospective",
        "multicenter",
        "clinical",
        "trial",
        "evaluating",
        "hf10",
        "therapy",
        "treatment",
        "chronic",
        "intractable",
        "neck",
        "upper",
        "limb",
        "pain",
        "demonstrated",
        "approximate",
        "reduction",
        "va",
        "pain",
        "score",
        "interim",
        "data",
        "prospective",
        "multicenter",
        "clinical",
        "trial",
        "evaluating",
        "hf10",
        "therapy",
        "treatment",
        "peripheral",
        "polyneuropathy",
        "led",
        "initiation",
        "randomized",
        "trial",
        "painful",
        "diabetic",
        "neuropathy",
        "demonstrated",
        "approximate",
        "reduction",
        "va",
        "pain",
        "score",
        "interim",
        "data",
        "multicenter",
        "feasibility",
        "study",
        "evaluating",
        "hf10",
        "therapy",
        "treatment",
        "chronic",
        "abdominal",
        "pain",
        "selected",
        "neurosurgery",
        "official",
        "journal",
        "congress",
        "neurological",
        "surgeon",
        "cns",
        "top",
        "pain",
        "paper",
        "year",
        "outcome",
        "publication",
        "fourth",
        "quarter",
        "financial",
        "result",
        "revenue",
        "quarter",
        "ended",
        "december",
        "million",
        "versus",
        "million",
        "period",
        "prior",
        "year",
        "representing",
        "growth",
        "reported",
        "revenue",
        "three",
        "month",
        "ended",
        "december",
        "million",
        "representing",
        "growth",
        "reported",
        "international",
        "revenue",
        "million",
        "representing",
        "growth",
        "constant",
        "currency",
        "basis",
        "increase",
        "revenue",
        "primarily",
        "attributable",
        "continued",
        "adoption",
        "senza",
        "system",
        "gross",
        "profit",
        "fourth",
        "quarter",
        "million",
        "representing",
        "gross",
        "margin",
        "million",
        "representing",
        "gross",
        "margin",
        "period",
        "prior",
        "year",
        "operating",
        "expense",
        "fourth",
        "quarter",
        "million",
        "compared",
        "million",
        "period",
        "prior",
        "year",
        "representing",
        "increase",
        "increase",
        "operating",
        "expense",
        "driven",
        "primarily",
        "increased",
        "headcount",
        "related",
        "personnel",
        "cost",
        "well",
        "legal",
        "expense",
        "associated",
        "intellectual",
        "property",
        "litigation",
        "loss",
        "operation",
        "fourth",
        "quarter",
        "million",
        "compared",
        "million",
        "period",
        "prior",
        "year",
        "revenue",
        "guidance",
        "full",
        "year",
        "nevro",
        "reiterates",
        "worldwide",
        "revenue",
        "range",
        "million",
        "first",
        "announced",
        "january",
        "webcast",
        "conference",
        "call",
        "information",
        "management",
        "host",
        "conference",
        "call",
        "today",
        "beginning",
        "pt",
        "et",
        "individual",
        "interested",
        "listening",
        "conference",
        "call",
        "may",
        "dial",
        "domestic",
        "caller",
        "international",
        "caller",
        "conference",
        "id",
        "access",
        "webcast",
        "investor",
        "section",
        "company",
        "web",
        "site",
        "nevro",
        "headquartered",
        "redwood",
        "city",
        "california",
        "nevro",
        "global",
        "medical",
        "device",
        "company",
        "focused",
        "providing",
        "innovative",
        "product",
        "improve",
        "quality",
        "life",
        "patient",
        "suffering",
        "debilitating",
        "chronic",
        "pain",
        "nevro",
        "developed",
        "commercialized",
        "spinal",
        "cord",
        "stimulation",
        "sc",
        "system",
        "neuromodulation",
        "platform",
        "treatment",
        "chronic",
        "pain",
        "system",
        "sc",
        "system",
        "delivers",
        "nevro",
        "proprietary",
        "therapy",
        "senza",
        "senza",
        "ii",
        "hf10",
        "nevro",
        "nevro",
        "logo",
        "trademark",
        "nevro",
        "statement",
        "addition",
        "historical",
        "information",
        "press",
        "release",
        "contains",
        "respect",
        "business",
        "capital",
        "resource",
        "revenue",
        "projection",
        "strategic",
        "initiative",
        "growth",
        "reflecting",
        "current",
        "belief",
        "expectation",
        "management",
        "made",
        "pursuant",
        "safe",
        "harbor",
        "provision",
        "private",
        "security",
        "litigation",
        "reform",
        "act",
        "including",
        "continuing",
        "adoption",
        "interest",
        "senza",
        "international",
        "market",
        "expectation",
        "worldwide",
        "revenue",
        "full",
        "year",
        "based",
        "upon",
        "information",
        "currently",
        "available",
        "u",
        "current",
        "expectation",
        "speak",
        "date",
        "hereof",
        "subject",
        "numerous",
        "risk",
        "uncertainty",
        "including",
        "ability",
        "successfully",
        "commercialize",
        "product",
        "ability",
        "manufacture",
        "product",
        "meet",
        "demand",
        "level",
        "availability",
        "payor",
        "reimbursement",
        "product",
        "ability",
        "effectively",
        "manage",
        "anticipated",
        "growth",
        "ability",
        "protect",
        "intellectual",
        "property",
        "right",
        "proprietary",
        "technology",
        "ability",
        "operate",
        "business",
        "without",
        "infringing",
        "intellectual",
        "property",
        "right",
        "proprietary",
        "technology",
        "third",
        "party",
        "competition",
        "industry",
        "additional",
        "capital",
        "credit",
        "availability",
        "ability",
        "attract",
        "retain",
        "qualified",
        "personnel",
        "product",
        "liability",
        "claim",
        "factor",
        "together",
        "described",
        "greater",
        "detail",
        "annual",
        "report",
        "form",
        "expect",
        "file",
        "february",
        "well",
        "report",
        "may",
        "file",
        "sec",
        "future",
        "may",
        "cause",
        "actual",
        "result",
        "performance",
        "achievement",
        "differ",
        "materially",
        "adversely",
        "anticipated",
        "implied",
        "expressly",
        "disclaim",
        "obligation",
        "except",
        "required",
        "law",
        "undertaking",
        "update",
        "revise",
        "result",
        "full",
        "year",
        "quarter",
        "ended",
        "december",
        "necessarily",
        "indicative",
        "operating",
        "result",
        "future",
        "period",
        "investor",
        "relation",
        "contact",
        "nevro",
        "investor",
        "relation",
        "katherine",
        "bock",
        "ir",
        "nevro",
        "consolidated",
        "statement",
        "operation",
        "comprehensive",
        "loss",
        "thousand",
        "except",
        "share",
        "per",
        "share",
        "data",
        "three",
        "month",
        "ended",
        "year",
        "ended",
        "december",
        "december",
        "unaudited",
        "revenue",
        "cost",
        "revenue",
        "gross",
        "profit",
        "operating",
        "expense",
        "research",
        "development",
        "sale",
        "general",
        "administrative",
        "total",
        "operating",
        "expense",
        "loss",
        "operation",
        "income",
        "expense",
        "interest",
        "income",
        "expense",
        "net",
        "income",
        "expense",
        "net",
        "loss",
        "extinguishment",
        "debt",
        "loss",
        "income",
        "tax",
        "provision",
        "income",
        "tax",
        "net",
        "loss",
        "change",
        "foreign",
        "currency",
        "translation",
        "adjustment",
        "change",
        "gain",
        "loss",
        "investment",
        "net",
        "change",
        "comprehensive",
        "loss",
        "comprehensive",
        "loss",
        "net",
        "loss",
        "per",
        "share",
        "basic",
        "diluted",
        "weighted",
        "average",
        "share",
        "used",
        "compute",
        "net",
        "loss",
        "per",
        "share",
        "basic",
        "diluted",
        "nevro",
        "consolidated",
        "balance",
        "sheet",
        "thousand",
        "except",
        "share",
        "per",
        "share",
        "data",
        "december",
        "december",
        "asset",
        "current",
        "asset",
        "investment",
        "account",
        "receivable",
        "net",
        "inventory",
        "net",
        "total",
        "current",
        "asset",
        "property",
        "equipment",
        "net",
        "asset",
        "restricted",
        "cash",
        "total",
        "asset",
        "liability",
        "stockholder",
        "equity",
        "current",
        "liability",
        "account",
        "payable",
        "accrued",
        "liability",
        "total",
        "current",
        "liability",
        "debt",
        "total",
        "liability",
        "stockholder",
        "equity",
        "common",
        "stock",
        "par",
        "value",
        "share",
        "authorized",
        "share",
        "issued",
        "outstanding",
        "december",
        "respectively",
        "additional",
        "capital",
        "accumulated",
        "comprehensive",
        "loss",
        "accumulated",
        "deficit",
        "total",
        "stockholder",
        "equity",
        "total",
        "liability",
        "stockholder",
        "equity",
        "view",
        "original",
        "content",
        "multimedia",
        "http",
        "source",
        "nevro",
        "corp"
    ]
}